We aimed to report the case of a Pakistani female who presented with MMD
and hyperthyroidism, and the worldwide literature review of the case
reports on MMD associated with hyperthyroidism. Methods: The study was
carried out using PRISMA’s recommendations. An electronic search on
PubMed, Cochrane Library, and Google Scholar was carried out. Articles
explaining the association between Moyamoya disease and thyroid-related
diseases were included. Results: A total of 31 studies were included in
the review, with the preponderance of Japanese females. The review has
systematically compiled in detail all the aspects of moyamoya syndrome
and thyroid disorders- from detailed histories of the included patients
to the treatment interventions used and their outcomes. Conclusion: The
authors are with the suggestion that more cases of MMD and its
association with other major factors should be presented in Pakistan as
well as in all parts of the world.
To the EditorAn article published recently by Voss et al. 1 "Anatomical reasons for failure of dual-filter cerebral embolic protection application in TAVR: A CT-based analysis" has interested us in it as it provides a vast amount of knowledge to its readers. The authors did remarkable work in trying to explain the relationship and tried to convey it as best they could. We would certainly not hesitate to state that it was a pleasure to read such incredible work by the authors. We agree with the authors that specific anatomical reasons may lead to dual-filter cerebral embolic protection failure. However, we would like to highlight a few points that would improve the quality of the document by mentioning them.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.